ARTICLE | Clinical News
Azeliragon: Additional Phase IIb data
August 1, 2016 7:00 AM UTC
Additional data from an 18-month, double-blind, U.S. Phase IIb trial in 399 patients with mild to moderate AD showed that once-daily 5 mg oral azeliragon significantly delayed time to cognitive deteri...